What sildenafil research does—and does not—tell us about tadalafil for hair loss, with prescribing risks and useful next steps.
Tadalafil is not an established treatment for androgenetic alopecia. Our September 21, 2026 evidence check did not identify a controlled human trial showing that daily oral tadalafil improves scalp hair growth. Research on sildenafil, another PDE5 inhibitor, does not establish a hair-loss dose or expected benefit for tadalafil.
If you already take tadalafil for a prescribed indication, that is a separate treatment decision. Do not add it to a hair regimen on the assumption that more blood flow means more regrowth.
The 2018 sildenafil study examined human-derived dermal papilla cells and hair follicles, plus a mouse model. It reported cell proliferation and growth-factor changes, and earlier entry into the growth phase after topical sildenafil in mice.
Human-derived cells are not the same as people taking a medicine. This experiment did not test oral tadalafil, measure its effect on human hair density, or establish the safety of combining it with minoxidil.
Human topical-sildenafil research also exists. NCT05369481 registered a comparison with topical minoxidil in men with pattern hair loss. At this review, its status was unknown and no results were posted in the registry. That record establishes a study plan, not a successful result. It also concerns a different drug and route from daily oral tadalafil.
A proposed mechanism can justify investigation without justifying treatment. To support tadalafil for hair loss, a study would need to test tadalafil itself, use a suitable comparison group, measure meaningful hair outcomes and report adverse effects over an adequate period.
A before-and-after photograph from someone also using finasteride, minoxidil or several new products cannot identify tadalafil's contribution. Scalp warmth, flushing or a gym “pump” is not a validated hair-growth outcome. There is no supported promise here of thicker hair after six months, nor a reason to describe the drug as a low-risk hair add-on.
Our scalp blood-flow evidence review explains the difference between measuring circulation and measuring treatment benefit.
The current US Cialis label, updated June 2026, lists erectile dysfunction and benign prostatic hyperplasia indications, not hair loss. Its warning about reduced blood pressure matters when other medicines are involved.
Adding tadalafil to oral minoxidil needs a prescriber's assessment of the whole medication list. Evidence that either drug has another legitimate use does not establish that their combination is appropriate for hair loss. Tadalafil should not be treated as protection against the cardiovascular effects of anabolic-steroid use.
Bring your hair-loss history, current medicines and treatment photographs to a clinician who can confirm the diagnosis and assess response. If the question is whether to change minoxidil route, use our oral versus topical minoxidil evidence guide to prepare that discussion.
For someone considering tadalafil only for hair, the missing evidence is a reason to avoid adding it. For someone prescribed it for another condition, discuss concerns with the prescriber rather than repurposing or changing it yourself.
Powered by BTST